Suppression of T Cell Activation and Collagen Accumulation by an Anti-IFNAR1 mAb, Anifrolumab, in Adult Patients with Systemic Sclerosis

Journal of Investigative Dermatology

Volumn 135, Issue 10, 2015, Pages 2402-2409

  Guo, Xiang ^a   Higgs, Brandon W ^a   Bay Jensen, Anne C ^b   Karsdal, Morten A ^b   Yao, Yihong ^a   Roskos, Lorin K ^a   White, Wendy I ^a  

^a MEDIMMUNE   (United States)

^b NORDIC BIOSCIENCE A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANIFROLUMAB; BIGLYCAN; C REACTIVE PROTEIN; CHEMOKINE; COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 2; COLLAGEN TYPE 3; COLLAGEN TYPE 5; COLLAGEN TYPE 6; CYTOKINE; ELASTIN; GELATINASE A; GELATINASE B; GROWTH FACTOR; INEBILIZUMAB; INTERFERON; MATRILYSIN; OSTEOCALCIN; PLACEBO; T LYMPHOCYTE RECEPTOR; VERSICAN; ALPHA BETA INTERFERON RECEPTOR; IFNAR1 PROTEIN, HUMAN; MEDI-546; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); COLLAGEN DEGRADATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOWN REGULATION; DOWNSTREAM PROCESSING; DRUG DOSE ESCALATION; DRUG EFFECT; EXTRACELLULAR MATRIX; FEMALE; GENE OVEREXPRESSION; GENE REPRESSION; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; MALE; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REPEATED DRUG DOSE; SINGLE DRUG DOSE; SKIN BIOPSY; SYSTEMIC SCLEROSIS; T LYMPHOCYTE ACTIVATION; UPREGULATION; ANALYSIS OF VARIANCE; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; DRUG EFFECTS; FOLLOW UP; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTE ACTIVATION; METABOLISM; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; T LYMPHOCYTE; TREATMENT OUTCOME;

ADULT; ANALYSIS OF VARIANCE; ANTIBODIES, MONOCLONAL; COLLAGEN TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; LYMPHOCYTE ACTIVATION; MALE; PATIENT SAFETY; RECEPTOR, INTERFERON ALPHA-BETA; RISK ASSESSMENT; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 84941413793     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2015.188     Document Type: Article

References (48)

1. Antonelli A, Ferri C, Fallahi P et al. (2008) CXCL10 (alpha) and CCL2 (beta) chemokines in systemic sclerosis-a longitudinal study. Rheumatology (Oxford) 47: 45-9
2. Atamas SP, Luzina IG, Dai H et al. (2002) Synergy between CD40 ligation and IL-4 on fibroblast proliferation involves IL-4 receptor signaling. J Immunol 168: 1139-45
3. Barascuk N, Genovese F, Larsen L et al. (2013) A MMP derived versican neoepitope is elevated in plasma from patients with atherosclerotic heart disease. Int J Clin Exp Med 6: 174-84
4. Barascuk N, Veidal SS, Larsen L et al. (2010) A novel assay for extracellular matrix remodeling associated with liver fibrosis: an enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neoepitope of type III collagen. Clin Biochem 43: 899-904
5. Bay-Jensen AC, Liu Q, Byrjalsen I et al. (2011) Enzyme-linked immunosorbent assay (ELISAs) for metalloproteinase derived type II collagen neoepitope, CIIM-increased serum CIIM in subjects with severe radiographic osteoarthritis. Clin Biochem 44: 423-9
6. Benjamini Y, Drai D, Elmer G et al. (2001) Controlling the false discovery rate in behavior genetics research. Behav Brain Res 125: 279-84
7. Carmona FD, Martin JE, Beretta L et al. (2013) The systemic lupus erythematosus IRF5 risk haplotype is associated with systemic sclerosis. PLoS One 8: e54419
8. Coelho LF, de Oliveira JG, Kroon EG (2008) Interferons and scleroderma-a new clue to understanding the pathogenesis of scleroderma? Immunol Lett 118: 110-5
9. Degiannis D, Seibold JR, Czarnecki M et al. (1990) Soluble interleukin-2 receptors in patients with systemic sclerosis. clinical and laboratory correlations. Arthritis Rheum 33: 375-80
10. Denton CP, Engelhart M, Tvede N et al. (2009) An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis. Ann Rheum Dis 68: 1433-9
11. Duncan MR, Berman B (1987) Persistence of a reduced-collagen-producing phenotype in cultured scleroderma fibroblasts after short-term exposure to interferons. J Clin Invest 79: 1318-24
12. Eloranta ML, Franck-Larsson K, Lovgren T et al. (2010) Type I interferon system activation and association with disease manifestations in systemic sclerosis. Ann Rheum Dis 69: 1396-402
13. Frances C, Branchet MC, Bletry O et al. (1988) Skin collagen from scleroderma patients before and after cyclosporin A treatment. Clin Exp Dermatol 13: 1-3
14. Genovese F, Barascuk N, Larsen L et al. (2013) Biglycan fragmentation in pathologies associated with extracellular matrix remodeling by matrix metalloproteinases. Fibrogenesis Tissue Repair 6: 1536-6
15. Goldberg A, Geppert T, Schiopu E et al. (2014) Dose-escalation of human antiinterferon-alpha receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study. Arthritis Res Ther 16: R57
16. Heickendorff L, Zachariae H, Bjerring P et al. (1995) The use of serologic markers for collagen synthesis and degradation in systemic sclerosis. J Am Acad Dermatol 32: 584-8
17. Higgs BW, Liu Z, White B et al. (2011) Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis 70: 2029-36
18. Hummers LK (2010) The current state of biomarkers in systemic sclerosis. Curr Rheumatol Rep 12: 34-9
19. Karsdal MA, Nielsen MJ, Sand JM et al. (2013) Extracellular matrix remodeling: The common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure. Assay Drug Dev Technol 11: 70-92
20. Kawai M, Masuda A, Kuwana M (2008) A CD40-CD154 interaction in tissue fibrosis. Arthritis Rheum 58: 3562-73
21. Komura K, Sato S, Hasegawa M et al. (2004) Elevated circulating CD40L concentrations in patients with systemic sclerosis. J Rheumatol 31: 514-9
22. Kramer A, Green J, Pollard J Jr et al. (2014) Causal analysis approaches in ingenuity pathway analysis. Bioinformatics 30: 523-30
23. Lavie F, Miceli-Richard C, Ittah M et al. (2007) Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann Rheum Dis 66: 700-3
24. Leask A (2006) Scar wars: Is TGFbeta the phantom menace in scleroderma? Arthritis Res Ther 8: 213
25. Leeming D, He Y, Veidal S et al. (2011) A novel marker for assessment of liver matrix remodeling: an enzyme-linked immunosorbent assay (ELISA) detecting a MMP generated type I collagen neo-epitope (C1M). Biomarkers 16: 616-28
26. Leeming DJ, Nielsen MJ, Dai Y et al. (2012) Enzyme-linked immunosorbent serum assay specific for the 7 S domain of collagen type IV (P4NP 7 S): a marker related to the extracellular matrix remodeling during liver fibrogenesis. Hepatol Res 42: 482-93
27. Liu X, Mayes MD, Tan FK et al. (2013) Correlation of interferon-inducible chemokine plasma levels with disease severity in systemic sclerosis. Arthritis Rheum 65: 226-35
28. Maere S, Heymans K, Kuiper M (2005) BiNGO: a cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks. Bioinformatics 21: 3448-9
29. Nagy Z, Czirjak L (2005) Increased levels of amino terminal propeptide of type III procollagen are an unfavourable predictor of survival in systemic sclerosis. Clin Exp Rheumatol 23: 165-72
30. Nielsen MJ, Nedergaard AF, Sun S et al. (2013) The neo-epitope specific PROC3 ELISA measures true formation of type III collagen associated with liver and muscle parameters. Am J Transl Res 5: 303-15
31. O'Reilly S, Hugle T, van Laar JM (2012) T cells in systemic sclerosis: a reappraisal. Rheumatology (Oxford) 51: 1540-9
32. Prescott RJ, Freemont AJ, Jones CJ et al. (1992) Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 166: 255-63
33. Rosenquist C, Fledelius C, Christgau S et al. (1998) Serum CrossLaps one step ELISA. first application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin Chem 44: 2281-9
34. Rusinova I, Forster S, Yu S et al. (2013) Interferome v2. 0: an updated database of annotated interferon-regulated genes. Nucleic Acids Res 41: D1040-6
35. Sargent JL, Milano A, Bhattacharyya S et al. (2010) A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity. J Invest Dermatol 130: 694-705
36. Sato S (1999) Abnormalities of adhesion molecules and chemokines in scleroderma. Curr Opin Rheumatol 11: 503-7
37. Skjot-Arkil H, Barascuk N, Register T et al. (2010) Macrophage-mediated proteolytic remodeling of the extracellular matrix in atherosclerosis results in neoepitopes: A potential new class of biochemical markers. Assay Drug Dev Technol 8: 542-52
38. Skjot-Arkil H, Schett G, Zhang C et al. (2012) Investigation of two novel biochemical markers of inflammation, matrix metalloproteinase and cathepsin generated fragments of C-reactive protein, in patients with ankylosing spondylitis. Clin Exp Rheumatol 30: 371-9
39. Solans R, Bosch JA, Esteban I et al. (2004) Systemic sclerosis developing in association with the use of interferon alpha therapy for chronic viral hepatitis. Clin Exp Rheumatol 22: 625-8
40. Steen VD, Engel EE, Charley MR et al. (1996) Soluble serum interleukin 2 receptors in patients with systemic sclerosis. J Rheumatol 23: 646-9
41. Streicher K, Morehouse CA, Groves CJ et al. (2014) The plasma cell signature in autoimmune disease. Arthritis Rheumatol 66: 173-84
42. Trocme C, Leroy V, Sturm N et al. (2006) Longitudinal evaluation of a fibrosis index combining MMP-1 and PIIINP compared with MMP-9, TIMP-1 and hyaluronic acid in patients with chronic hepatitis C treated by interferonalpha and ribavirin. J Viral Hepat 13: 643-51
43. Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98: 5116-21
44. Valentini G, Della Rossa A, Bombardieri S et al. (2001) European multicentre study to define disease activity criteria for systemic sclerosis. II. identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 60: 592-8
45. Veidal SS, Karsdal MA, Nawrocki A et al. (2011a) Assessment of proteolytic degradation of the basement membrane: a fragment of type IV collagen as a biochemical marker for liver fibrosis. Fibrogen Tissue Rep 4: 22
46. Veidal SS, Karsdal MA, Vassiliadis E et al. (2011b) MMP mediated degradation of type VI collagen is highly associated with liver fibrosis-identification and validation of a novel biochemical marker assay. PLoS One 6: e24753.
47. Veidal SS, Vassiliadis E, Bay-Jensen AC et al. (2010) Procollagen type I N-terminal propeptide (PINP) is a marker for fibrogenesis in bile duct ligation-induced fibrosis in rats. Fibrogenesis Tissue Repair 3: 5
48. Yellin MJ, Winikoff S, Fortune SM et al. (1995) Ligation of CD40 on fibroblasts induces CD54 (ICAM-1) and CD106 (VCAM-1) up-regulation and IL-6 production and proliferation. J Leukoc Biol 58: 209-16